Multicenter real-world data of antifibrotics in non-IPF progressive pulmonary fibrosis (PPF) patients
Bildiriler > Özet Bildiri · 2024
Yazarlar: NESRİN ÖCAL, AYKUT ÇİLLİ, Nesrin MOĞULKOÇ BISHOP, NECMİYE FUNDA COŞKUN, AHMET URSAVAŞ, İSMAİL HANTA, BERNA AKINCI ÖZYÜREK, KEREM ENSARİOĞLU, ALPER ERZİNCAN, ESRA YÜKSEL, BESTE ARIKAN, FATİH ÜZER, TUĞÇE ŞAHİN ÖZDEMİREL, SALİM MISIRCI, PELİN PINAR DENİZ, İLKNUR BAŞYİĞİT, ÖZLEM ÖZDEMİR KUMBASAR
ILD/DPLD of known origin, Avusturya, Viyana, Uluslararası, Sözlü Sunum, Özet Bildiri, 2024-2024, ss PA697-PA697
DOI: 10.1183/13993003.congress-2024.pa697
Özet
In this multicenter retrospective cohort study, we aimed to reveal the real-world data of PPF patients, and the effectiveness and reliability of AFs. Adult patients diagnosed with PPF and treated with AFs for at least 6 months were examined. A total of 222 patients were included in the study. Autoimmune disease-related ILD, fHP and fNSIP were the most common subtypes. Nintedanib (N) (70.3%) was utilized more than pirfenidone (P) (27.5%). The mean of FVC%, FVC (ml), DLCO% at the 0th, 6th and 12th months showed significant differences with temporal decreases [F(1.895, 217.75)=6.573, p=0.002, F(1.513, 160.341)=3.547, p=0.043 and F(1.741, 194.973)=3.383, p=0.002 respectively]. When the losses in the first 6 months and the second 6 months were compared, only DLCO% had a significant difference (p=0.014). The decrease in FVC values was stable. In PPF subgroup analysis; the radiological pattern, AF regimen, duration of treatment before AF, and AF duration after diagnosis had significant differences between groups (p=0.001, p=0.001, p=0.008, and p=0.014, respectively). Those under N treatment needed more additional treatment than the P group (67.3 vs 42.6%, p=0.001). While all PFT values had reduced more in the N group (p:0.013, 0.028, and 0.012, respectively), the P group, had a higher hospitalization rate and an overall longer duration of AF treatment (p=0.037 and p=0.001 respectively). There was no significant difference regarding clinical and radiological findings, and also PPF subgroups in terms of mortality. Only radiological progression was significantly associated with mortality (p=0.001). Conclusionally, AFs show consistent efficacy in PPF.